Sarepta Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.4B-21.8% YoYTTM through 30 Jun 2026
Net Income -$136.7M-158.1% YoYTTM through 30 Jun 2026
Free Cash Flow $81.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 85.1% |
| EBITDA Margin | -7.0% |
| Operating Margin | 49.0% |
| Net Margin | -9.8% |
Returns
22.0%ROE
10.4%ROA
Balance Sheet Health
Debt / Equity0.56x
Current Ratio4.63x
Net Debt$185M
Cash & Equivalents$571.1M
Quality Metrics
Altman Z-Score-0.27
Piotroski F-Score3 / 9
FCF Margin5.9%
Rule of 4037.2
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $2.2B
Diluted EPS-$1.60TTMFY2025: $-7.13
Dividend
No dividend
Capital Allocation
Capex Intensity2.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| PMO Products | $228.6M | View detailsModest year-over-year decline anticipated due to ELEVIDYS cannibalization. | |
| ELEVIDYS Product | $102M | View detailsPositioned to return to growth with expanded field reach and educational initiatives. | |
| Collaboration and Other Revenues | $400M | View detailsFull year 2026 collaboration, contract manufacturing, and royalty revenues projected at $450 million to $550 million. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.